This method for assaying digoxin in serum with improved specificity combines small-column extraction of serum, "high-performance"liquid chromatography,and RIA of the elutedfractions.Analyticalrecoveriesof 1.0, 0.5, and 0.1 sg/ L standards were 95%, 93%, and 84%, respectively. The CVs forduplicatesand replicates of sera with valuesof 0.5 to 1 p/L were 4 to 6%. Fifty-nine sera from 50 patients receiving digoxin were so studied. All digoxin metabolites appear to cross react with antibody to digoxin to various degrees. The most polar metaboliteswere quantitativelythe mostimportant,theiraverage crossreactivitybeing33%. For eight patients the value for digoxin by the present method was <60% of the AlA value. Sera from nine patients not taking digoxinbut with falsely high digoxinvalues were also studied by the present method. The digoxin peak was well resolved from those for (a) digoxin metabolites (except dihydrodigoxin),(b) digitalis-likefactors in neonates and in patients with renal failure or combined hepatic and renal failure, and (c) two cross reacting drugs and their metabo- Compounds that give falsely high results in radioimmunoassay (NA) for digoxin reportedly include endogenous compounds in neonates (1, 2) and in pregnancy (3), renal failure (4), and combined hepatic and renal failure (5); drugs and (or) their metabolites (6); and metabolites of digoxin (7-9). More-specific methods are needed, both for clinical and medical-legal purposes.
in which only the HPLC peak for digoxin is determined.
We report here: (a) details of this combined HPLC/RIA method for "true" digoxin and metabolites;
(b) its precision and sensitivity; (c) the cross reactivity of certain digoxin metabolites with antibody to digoxin, and (d) our findings of clinically important false concentrations of digoxin caused by some endogenous compounds and certain drugs.
Materials and Methods

Patients
Group Ia: Blood sampled on 40 occasions from a total of 33 patients on long-term therapy with digoxin (longer than one month) was assayed for digoxin by HPLCIRIA and by an RIA (Kallestad, Austin, TX 78701). Blood was collected at steady state for assay, i.e., at least 18 h after the last daily dose. A serum sample from one patient was assayed 10 times for replicate studies; only the average value is included in the results for these 40 sera.
Group Ib: We studied samples from 17 patients on 19 occasions by both HPLC/RIA and the HPLC/radioassay methods, as well as with the Kallestad RIA. Blood for the HPLC/radioassay analysis was usually collected for analysis We have shown previously (7) that the proportion of metabolites 6 and 24 h after ingestion of digoxin does not differ greatly; we chose 6 h because, after longer periods, the quantity of radioactivity incorporated in several of the minor metabolites was insufficient for reproducible measurement in patients with normal renal function.
Group II: Nine sara, including one sample of pooled sara from five neonates and two sera from cord bloods, were assayed to ascertain the presence of endogenous digitalislike factors, or of drugs and (or) their metabolites crossreacting with antibody to digoxin. None of these patients had received digoxin.
Procedures
Preparation of standards. 
B. Assay of serum from patients receiving digoxin
Mean analytical recovery of digoxin standards added to digoxin-free serum ranged from 84 to 95% (Table 1) .
All 50 HPLC fractions for 27 Group Ia samples were assayed for "digoxin" (i.e., digoxin and all its metabolites) by RIA. As another measure of recovery, we compared the sum of the results for the 50 fractions with the RIA value for digoxin in an unprocessed serum. The average proportion of digoxin accounted for (as measured by HPLC/RIA) was 97% of that measured by RIA alone (range 88% to 108%, SD 5.3%). For three batches of Bond-Elut columns the recoveries averaged 99% (n = 2), 98% (n = 5), and 94% (n = 11), and recovery was 99% for one batch of Sep-Pak columns (n 0.04 4 95 9). heim, Dorval, Quebec, Canada H9P 9Z9) in methanol, evaporating aliquots, and diluting with digoxin-free serum to give the concentrations shown below in Table 1 . HPW/RIA method. We extracted digoxin and its metabolites from 1 mL of serum by using one of three batches of C18 reversed-phase "Bond-Elut" columns (Analytichem, Harbor City, CA 90700), or a single batch of C18 reversed-phase "Sep-Pak" columns (Waters Associates, Milford, MA 01757).
After successively washing the column with 6 mL of methanol and 3 mL of water, we applied 1 mL of serum to the column, washed with 1 mL of water, and discarded the eluate. We then eluted digoxin and metabolites from the column with 3 mL of methanol. After evaporating the eluate in a stream of ifitered air at ambient temperature, we reconstituted For Group Ia samples, we then collected 50 1-mL fractions in RIA tubes for a complete study for 27 sara, but only collected 10 fractions for studies designed simply to define the digoxin peak for 13 sara. The solvent was evaporated under a stream of ifitered air, which gives the same results as nitrogen (7), and the residue was reconstituted with 100
4 of digoxin-free plasma for assay by RIA. The HPLC instruments used have been previously reported (7) . We used Kallestad reagents (lmIlabeled digoxin) for assay of samples from Groups Ia and Ib, and reagents from New England Nuclear, Boston, MA 02118, for Group II samples. When these kits were used in the usual manner to assay serum digoxin, we have used the abbreviation RIA, in contrast to use of the more-specific present HPLC/RIA method.
Cross reactivity studies.
Studies on the mono -and bisdigitoxosides of digoxigernn, 3a-, 3/3-, and 3-keto-digoxi- isopropanol, switching to 200 mLIL at 40 mm. Each of 100 chromatographic fractions collected was divided into two aliquots; one was assayed for digoxin and metabolites by use of the Kallestad RIA and the other by counting the tritium radioactivity.
Polar metabolites.
The polar metabolites are defined as those appearing as the first two peaks in the HPLC procedure. These compounds are poorly extracted with solvents such as chloroform and methylene chloride. Excludedfrom the polar metabolites are the mono-and bis-digitoxosides of digoxigenin; 3-keto-, 3a-, and 3/3-digoxigenin; and dihydrodigoxin.
To obtain a value for average cross reactivity of the polar group of metabolites with antibody to digoxin, we combined data from the HPLC/RIA and the HPLC/radioassay.
In both for a given column during any week (± 1 mm) and over the life of a given column (±2 mm). Figure 1 illustrates the results of the HPLC/RIA method for two digoxin standards in sara and for sara from two patients, one of whom had minimal and the other extensive digoxin biotransformation.
The retention time for the digoxin peak was uniformly 34 mm. We calculated the digoxin concentration by summing the values for the individual fractions in the digoxin peak.
If we take the retention time of digoxin to be 34 mm, the retention time for the bis-digitoxoside is 19 mm, for the mono-digitoxoside 12 mm, and for a-and $-digoxigenin and ketodigoxigenin 9 mm ( Figure 1A) . 
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When serum was collected for assays on more thanone day (seven patients),the averagevaluewas used. Figure 3 illustrates HPLC/RIA proifies for four samples containing endogenous components of serum or drugs and metabolites that interact with RIAs for digoxin to give falsely high values. None of the patients shown were receiving digoxin, and none of the elution profiles had a peak with the same retention time as for digoxmn. Figure 3A shows the profile for a pool of five cord-blood specimens, for which the value for digoxin by RIA was 0.84 igfL. The interacting material had a retention time similar to that for the polar metabolites of digoxin. Serum from a patient with dialysis-dependent renal failure gave a similar elution profile (apparent digoxin = 0.3 1zgfL). Figure 3C showsthe multiple peaks obtained with serum from a patient with combined hepatic and renal failure; the peak with a retention time of 25 mm contained bile salts in high concentration.
Interference from digitalis-like factors and drugs and metabolites (Group H).
Other cross-reactivity studies. Results of other cross-reactivity studies are listed in Table 3 . 
Discussion
Assessment of Method
The CV for determinations of duplicates and replicates ranged from 4 to 6%, comparable with CVs reported for unmodified RJAs (12, 13) . The low between-day and between-technician CVs for control sera, the high analytical recoveries, and the reproducibility of results with different However, this method may miss some nondigoxin-reactive compounds in the procedure. In another study, three of our patients with combined hepatic and renal failure who were not taking digoxin had a concentration of digoxin (by RJ.A of unprocessed serum) of 0.7, 1.7, and 1.8 ,ug/L (5). Only about 50% of the material causing the false digoxin values was accounted for in their serum samples, the rest being lost in the Bond-Elut extraction step. If such a patient were receiving digoxin and the losses were thought to be digoxin, a correction based on the "internal" recovery would give a falsely high result for digoxin. In the study reported here, the analytical recoveries obtained by summing RJA digoxin values in all 50 fractions per sample ranged from 88% to 108% (mean 97%); however, none of these patients was jaundiced.
The improved specificity of the method is its major advantage. To date, we have found no drugs, endogenous compounds, or digoxin metabolites (except dihydrodigoxin) that are eluted at the same time as digoxin. Nevertheless, for medical-legal purposes, greater specificity is desirable; with this method we can only say that a compound is not digoxin, but not categorically that it is digoxin.
Major disadvantages
are the time involved and the cost.
We collect 10 1-mL fractions of the HPLC eluate to define the digoxin peak, and determine the digoxin concentration on each fraction by RIA. For duplicate determinations of each of the 10 fractions, the minimum cost per test currently would be about $30, including labor, about 10-fold that estimated for duplicate determinations with the usual RIAs.
However, we are investigating the possibility of reducing the number of fractions appreciably without loss of preci-
Digoxin Metabolites
Our values for cross reactivity of the different metabolites as measured with six different kits (Table 3) correspond to those reported elsewhere (7,9,14-18) .
Biotransformation of digoxin can be extensive (7, 8, 19,   20 ). In 19 sera from Group lb studied by HPLC/radioassay, metabolites accounted for from 1 to 99% of the total radioac-tivity in plasma and averaged 40%, as compared with 35% for the polar metabolites. Thus, the polar metabolites were, on average, 88% of the total metabolites. Of the RIA value for unprocessed serum, 40 to 70% was found to be ascribable to polar metabolites in eight of 50 patients studied by HPLC/RIA (Figure 2) . Assay of digoxin by the HPLCIRIA and HPLC/radioassay methods gives equivalent results, because both methods measure the actual amount of digoxin in the serum. However, the HPLC/RIA method gives a lower value than the HPLC/radioassay method for metabolites, because those in the polar group especially have <100% cross reactivity with the antibody to digoxin used in this study. The true metabolite concentration somewhat exceeds twice the difference between the RIA and HPLCIRIA values.
The clinical significance of the polar metabolites relates to the fact that they have an average of 33% cross reactivity with antibody to digoxin, but in all probability they have little cardioactivity (7, (21) (22) (23) (24) ). Thus, a major degree of underdosing could result, as it did in the patient whose results are shown in Figure l#{192} .
The polar group of metabolites appears to consist of several compounds, including the glucuronide and sulfate conjugates of 3a(epi)-digoxigenin (7,9,19). The considerable variation found in apparent cross reactivity (33%, SD 25%)
suggests that there may be an important variability in the relative amounts of the individual polar metabolites from patient to patient, and that their cross reactivity may vary.
The less-polar minor metabolites measured by RIA for digoxin probably will have little clinical significance. The mono-and bis-digitoxosides of digoxigenin and 3-keto-, 3a-, and 3p-digoxigenin ordinarily are individually
<3% and
collectively <15% of the sum of digoxin and its metabolites, as found by our HPLC/radioassay (7) of serum and urine, and often <7-8% (7) . Also, both the cross reactivity and the cardioactivity of the mono-and bis-digitoxosides of digoxigenin (14-17, 22, 25) are roughly equal to that of digoxin itself. In contrast, the cross reactivity of 3J3-digoxigenin in most studies (15-17) approaches 100% but the cardioactivity is only 10 to 50% of that of digoxin.
Dihydrodigoxin, which is co-eluted with digoxin in this method, reportedly (18) had <12% cross reactivity with antidigoxin antibody in six commercial digoxin kits. We found values of <3% for six kits and confirmed the 2% value given by Kallestad Labs. for the antibody used in this study. Hence, the contribution of dihydrodigoxin to an RIA value, even when present in maximum reported amounts-e.g., (18, 26)-may be considered trivial. In addition, only about 10% of patients form important amounts of reduced metabolites, and the cardioactivity of dihydrodigoxin and other dihydro metabolites is slight (22, 26) . Nevertheless, it is important to appreciate that when a patient is receiving antibiotics that kill the intestinal bacteria that form dihydrodigoxin and dihydro metabolites, there may be a major decrease in dihydrodigoxin and a corresponding increase in digoxin of up to 100%, with the danger of overdosage (26) . Although their RIA cross reactivity with antibody to digoxin is not often clinically significant, we illustrate that administration of large doses of spironolactone ( Figure 3C ) and 6-methylprednisolone ( Figure 3D ) can produce clinically important increases in apparent digoxin in the usual RI-A,but not with the present HPLC/RIA method. None of the endogenous digitalis-like factors or drugs we evaluated by HPLC/RIA in this study led to an HPLC/RIA peak with the retention time of digoxin (Figures 1 and 3) , but the possibility that such non-digoxin compounds exist can by no means be excluded, and this has medical-legal significance. Thus, this method can confirm the absence of digoxin, but can not absolutely prove its presence.
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